Did the Drug Get There, & Did It Work? Verifying Target Access, Drug Engagement & Clinical Translation in Ophthalmic Drug Delivery
10:30 am - Thursday 21st January 2027
- Showcase proving placement with the Near-Real Surgical Specimens (NRSS), a reperfused human ocular tissue platform, as the true human analog for testing delivery devices, with real-time OCT and contrast visualization of suprachoroidal access (inter-specimen CV 6.8% vs 17.7% in cadaveric eyes; TVST 2025)
- Demonstrate accelerated from bench to investigator translation and how the same platform trains and certifies trial PIs on suprachoroidal gene-therapy injection (ICG confirmation of the space) and de-risks first-in-human studies across multiple sponsor programs
- Introduce TEMPO tear proteomics from a Schirmer strip as a non-invasive pharmacodynamic readout, ~3,000 proteins, quantified receptor-pathway inhibition and washout after an IGF-1R biologic in thyroid eye disease, and what this means for precision dosing and payer evidence
